PUREPAC PHARM
GenericsPUREPAC PHARM is a generic drug manufacturer focused on Immunology, Cardiovascular, Neurology.
PUREPAC PHARM's Key Drugs
PUREPAC PHARM's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
PUREPAC PHARM's Recent FDA Approvals
New NDA/BLA approvals for PUREPAC PHARM over the last two years — novel drugs only, excluding generics and label supplements.
PUREPAC PHARM's Therapeutic Areas
PUREPAC PHARM's approved drugs and pipeline span 5 therapeutic areas, led by Immunology and Cardiovascular, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
PUREPAC PHARM's Top Competitors
PUREPAC PHARM's closest competitors by therapeutic-area and drug-target overlap include Pfizer, PAI HOLDINGS PHARM, and BAUSCH AND LOMB INC. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
PUREPAC PHARM Pipeline Snapshot
Active clinical trials for PUREPAC PHARM across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Immunology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1972-11-02
- Latest
- 2001-11-02
- Applications
- 130